What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

Haliza Md Kasim’s eyes widened. Despite having gone through this before with her first son, Yusof, and despite the doctors ...

Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems.

One of the treatments, for a progressive disorder known as Hunter syndrome, could secure approval in the U.S. as soon as late ...

It should be applied twice daily at least 8 hours apart. The treated area should not be washed for at least 4 hours after application of the medication. Its primary action is that of hair growth ...

In practice, burning feet syndrome is very often related to a deficiency of vitamin B5 (pantothenic acid). Other potential symptoms which may point to a deficiency of this nutrient include ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

This designation is in addition to Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, all previously granted by the FDA for tividenofusp alfa in Hunter syndrome.

Hunter syndrome affects over 2,000 individuals, primarily males, in commercially accessible regions. With analysts maintaining a Strong Buy consensus and the company maintaining a healthy liquidity ...